JGC
STML

J. Goldman & Co’s Stemline Therapeutics, Inc. STML Stock Holding History

J. Goldman & Co’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-20,000
Closed -$307K – 411
2019
Q2 		$307K Buy
+20,000
New +$289K 0.02% 237

Other funds holding STML

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

J. Goldman & Co's STML Position: Q1 2020 in Review

J. Goldman & Co sold out of Stemline Therapeutics, Inc. (STML) in Q1 2020, closing a stake of 177,602 shares — an estimated $1.89M sold.

J. Goldman & Co first reported a position in STML in Q4 2016 and held it in 11 quarters. The position peaked at $5.81M in Q3 2019. 94 funds tracked by Wall St. Rank hold STML as of Q1 2020.

  • J. Goldman & Co reported no remaining Stemline Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
  • J. Goldman & Co sold 177,602 Stemline Therapeutics, Inc. shares in Q1 2020, an estimated $1.89M.
  • J. Goldman & Co first reported a position in Stemline Therapeutics, Inc. in Q4 2016 and held it in 11 quarters.
  • J. Goldman & Co's Stemline Therapeutics, Inc. position peaked at $5.81M in Q3 2019.
  • 94 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2020.

Based on J. Goldman & Co's 13F filing for Q1 2020, filed 15 May 2020.